ICCBBA, the international standards organization responsible for the management and development of the ISBT 128 Standard, is a not-for-profit nongovernmental organization in official relations with the World Health Organization (WHO).
ICCBBA Vision, Mission, & Priorities

**VISION**
Global adoption of ISBT 128 for all medical products of human origin.

**MISSION**
Enhancing patient safety by promoting and managing the ISBT 128 international information standard for use with medical products of human origin.

**PRIORITIES**
1. To manage international information standards for transfusion medicine, transplantation, and other applications of medical products of human origin in support of traceability, biovigilance, and patient safety.
2. To liaise with health authorities, regulators, scientific and professional societies, user communities, and vendors on standardization in terminology and information technology.
3. To provide educational programs to promote the value of, and need for, information standards and policies to support traceability and biovigilance.
4. To provide technical consultation regarding the implementation and management of ISBT 128.
5. To lead in the continued development of common data structures for information technology, data processing, exchange and transfer, and labeling for medical products of human origin.
ICCBBA Board Members

ICCBBA is governed by a volunteer Board of Directors comprising leading experts in blood transfusion, cellular therapy, and tissue transplantation from around the world. Board positions are advertised publicly and Board members normally serve six year terms. The current Board of Directors has members from Belgium, Germany, India, The Netherlands, Bhutan, the United States, and the United Kingdom.

The governance role of the Board ensures that ICCBBA is managed in an effective and efficient manner and is appropriately staffed and funded whilst at the same time ensuring a fee structure that is fair and appropriate. As Board Members receive no remuneration, and have no long term association with ICCBBA they can maintain the necessary balance and independence to ensure stakeholders receive good value for money.

In this way the ICCBBA Board of Directors has ensured that ICCBBA has developed in a sustainable and responsible manner since its creation in 1994, and will continue to ensure effective controls and efficiencies as ISBT 128 moves forward as the International Standard for Medical Products of Human Origin.
### Operating Income

#### Registration Fees
- 33,387

#### License Fees - Facilities
- 1,298,022

#### License Fees - Vendors
- 532,835

#### Forum 25
- 4,338

**TOTAL**
- 1,868,582

#### Staff Costs
- 1,231,323

#### Scientific Congresses & Exhibitions
- 90,558

#### Technical, Development & Board Meetings
- 164,086

#### Office Expenses
- 42,241

#### Office Rental
- 93,929

#### Donations and Awards
- 11,547

#### Professional Services
- 27,034

#### Communication Services
- 39,870

#### Staff Administrative Travel
- 7,766

#### Banking Fees
- 25,595

#### Insurance
- 20,964

#### Forum 25
- 185,399

**TOTAL EXPENDITURE**
- 1,940,309

**Net Operating Income**
- 71,727

**TOTAL**
- 1,868,582
### 2019 Balance Sheet

#### ASSETS

<table>
<thead>
<tr>
<th>Current Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>354,290</td>
</tr>
<tr>
<td>Interest Receivable</td>
<td>1,533</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td><strong>355,823</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equipment</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Office Furniture &amp; Equipment</td>
<td>58,850</td>
</tr>
<tr>
<td>Computer Hardware &amp; Software</td>
<td>58,246</td>
</tr>
<tr>
<td>Less Accumulated Depreciation</td>
<td>101,423</td>
</tr>
<tr>
<td><strong>Total Equipment</strong></td>
<td><strong>15,673</strong></td>
</tr>
<tr>
<td>Deposits</td>
<td>6,254</td>
</tr>
<tr>
<td>Investments</td>
<td>2,974,018</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>3,351,768</strong></td>
</tr>
</tbody>
</table>

#### LIABILITIES & NET ASSETS

<table>
<thead>
<tr>
<th>Current Liabilities</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Credit Card Liability</td>
<td>13,335</td>
</tr>
<tr>
<td>Other</td>
<td>2,336</td>
</tr>
<tr>
<td>Accrued Pension Contributions</td>
<td>27,857</td>
</tr>
<tr>
<td><strong>Total Current Liabilities</strong></td>
<td><strong>43,528</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets - Unrestricted</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Undesignated</td>
<td>1,506,122</td>
</tr>
<tr>
<td>Designated</td>
<td>1,802,118</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>3,308,240</strong></td>
</tr>
</tbody>
</table>

**TOTAL LIABILITIES & NET ASSETS:** 3,351,768
A HISTORY OF ICCBBA: 1994 - 1995

1994

- The United States Department of Defence and Baxter Healthcare in Deerfield, Illinois provide a three year grant to assist in the establishment of the office where ICCBBA will eventually be created.
- AABB and American Red Cross appoint members to form a Board of Directors for new office. The ISBT Council approves the ISBT 128 Standard and agrees in principle to form ICCBBA by adding members to the CoCBBBA Board of directors. CoCBBBA was the original Council for Commonality in Blood Banking Automation, Inc. - a committee established by the AABB, before evolving into ICCBBA.

1995

- In February, ICCBBA's Board of Directors meet, writes bylaws, establishes a budget, and prepares Articles of Incorporation for the subsequent incorporation of ICCBBA in the Commonwealth of Virginia.
- ISBT Council formally cedes ownership of ISBT 128 to ICCBBA, Inc.
- In November the first full Board of Directors meeting commences. The Americas Technical Advisory Group (ATAG) is established to advise ICCBBA on needs of users in the Americas.
- ISCBBA, Inc. receives not-for-profit status from the US Internal Revenue Service.
- The Blood Products Advisory Committee of the FDA votes in March of this year to recommend the use of ISBT 128 in the US according to a timetable presented by ICCBBA, Inc.
- ICCBBA publishes version 1.0.0 of the document “Bar Code Symbology and Application Specification for Labeling of Whole Blood and Blood Components.”
- Registration and license fees are established and the first vendor registers with ICCBBA.

1996
- ICCBBA Board of Directors establishes policies for release of incorporated owned materials.

1997
- First Product Description Codes were added to the Product Description Code Database in the category of whole blood in July of 1996.
- Version 1.0.0 of the US Industry Consensus Standard is published.

1998
- A facility in Norway becomes the 50th vendor that registers with ICCBBA.
- 1,000th facility registers with ICCBBA.
- ICCBBA Technical Advisory Groups (TAGs) are formed to provide stakeholder input to the ongoing development of the ISBT 128 Standard and to provide educational and technical support to facilities implementing ISBT 128.
- Estonia becomes the 10th country to be registered with ICCBBA and implemented the use of ISBT 128.
- Talks about about implementing ISBT 128 in Estonia begin in the first meeting of European Technical Advisory Group (ETAG).

Estonia becomes the 10th country to be registered with ICCBBA and implemented the use of ISBT 128.
A HISTORY OF ICCBBA: 1999 - 2002

1999
- ICCBBA publishes the ISBT 128 US Consensus Standard as a guidance document.
- Number of registered facilities reaches 1,500.

2000
- In the United Kingdom, NHS Blood & Transplant is the first tissue facility that registers with ICCBBA.

2001
- MEETAG (EMATAG) MEMBERS IN CAIRO, EGYPT

2002
- 4,000th Product Description Code added.
- ATTENDING CONGRESSES
  On a yearly basis, ICCBBA staff travel to various congresses worldwide to spread awareness of ICCBBA's mission of the global adoption of ISBT 128 for all medical products of human origin.
- St. Luke's Episcopal Hospital in Houston, Texas becomes the first facility in the United States to implement ISBT 128 in its blood bank.
A HISTORY OF ICCBBA: 2003 - 2005

2003
- The United Kingdom and Switzerland implement ISBT 128 nationally for blood transfusions.
- Mexico becomes 25th country to have registered facilities licensed to use ISBT 128 with ICCBBA.

2004
- Kuwait implements ISBT 128 as a national solution in blood banking.
- A facility in Turkey becomes the 100th vendor that registers with ICCBBA.

2005
- The 5,000th Product Description Code in the category of blood is added.
- Hospitals in Norway start to use secure wristband identification using ISBT 128 data structures.
2006

ICCBBA updates the Product Description Code database by adding 74 product codes for the following countries: US, UK, Canada, Sweden, China, and Singapore.

The Cellular Therapy Coding and Labeling Advisory Group (CTCLAG) is formally established to develop terminology and labeling standards for Cell Therapy applications.

2007

The 100th Cellular Therapy facility registers with ICCBBA.

The Asia Pacific Technical Advisory Group (AFTAG) is formed to advise ICCBBA on the needs of users in the Asia Pacific Region.

2008


The CT advisory group publishes standards for the terminology and labeling of cellular therapy products, further expanding the role of ISBT 128 to a standardized terminology system.

A AABB required its accredited blood banks to implement ISBT 128 by May of 2008.

ICCBBA creates One World Award to acknowledge professionals who contribute to the understanding and application of international information standards in transfusion and transplantation medicine.

By mid 2008, Colombia becomes the 50th country to have facilities registered with ICCBBA.
A HISTORY OF ICCBBA: 2009 - 2011

ICCBBA partners with the International Blood Emergency Planning Action Group (IBEPAG) to carry out a survey that tabulated which blood institutions had implemented or were planning on implementing ISBT 128.

First meeting of the European Tissue Technical Advisory Group (ETTAG) occurs in Krakow, Poland.

The World Health Assembly passes resolution WHA63.22 which urges Member States to encourage the implementation of globally consistent coding systems for human cells, tissues, and organs.

The journal of the ISBT, Vox Sanguinis, publishes Standard Terminology for Platelet Additive Solutions.

The World Health Assembly passes resolution WHA63.22 which urges Member States to encourage the implementation of globally consistent coding systems for human cells, tissues, and organs.

The One World Award is Presented to Dr. Charles Munk, its first recipient.

ICCBBA enters into official relations with the World Health Organization.

First year that ICCBBA becomes ISO 9001 certified.


FIRST ONE WORLD AWARD RECIPIENT: DR. CHARLES MUNK

DR. CLIVE HOHBERGER: 2011 ONE WORLD AWARD WINNER
A HISTORY OF ICCBBA: 2012 - 2015

2012

5,000 Facilities
5,000th facility registers with ICCBBA.

First conference call for Milk Banking Technical Advisory Group (MBTAG).

2013

Dr. Edwin A. Steane is presented with the One World Award. Dr. Steane was previously the first Executive Director of ICCBBA as well as one of the original creators of the ISBT 128 Standard.

2014

ICCBBA celebrates 20th anniversary in 2014

WHO-ICCBBA Joint Workshop in Annecy, France

ICCBBA releases version 1.0 of the Product Lookup Program.

2015

FDA's Center for Devices and Radiologic Health (CDRH) approves ICCBBA as one of only three issuing agencies for medical device Unique Device Identifiers (UDI) in the US.

WHO-ICCBBA Joint Workshop in Annecy, France

Gameta Szpital Sp. Z.O.o. in Poland becomes the first reproductive facility to register with ICCBBA.

The European Commission publishes directive that recognizes ISBT 128 to be compatible with the SEC.
Version 1.0 of an implementation guide on blood transfusion for resource limited countries is published. The intended audiences of this document are blood transfusion services and hospital blood banks.

ICCBBA releases version 1.0 of the Product Lookup Program.

Enterobiotics, Ltd. In Scotland becomes the first fecal microbiota facility that registers with ICCBBA.

ICCBBA releases version 1.0 of the Single European Code Builder Tool.

AABB, FACT, JACIE, and NMDP require that ISBT 128 terminology be used when labeling cellular therapy products. AABB Standards for Cellular Therapy requires that all facilities shall implement ISBT 128 labeling by 01 July 2018.

The Eye Bank Association of America (EBAA) requires ISBT 128 barcoding for international shipments for eye banks in North America. ICCBBA releases a guidance document (IG-040) in relation to this.

The first Enterprise Grant is awarded to Global Healing, a nonprofit organization based in Berkeley, California, for its proposal to strengthen the quality management system of the blood bank at the Hôpital Universitaire de Mirebalais (HUM) in Haiti.

ICCBBA releases version 1.0 of the Cellular Therapy Audit Tool. The tool is intended for auditors to help them assess compliance to ISBT 128 requirements for cellular therapy products as well as used by facilities wanting to perform a self-assessment or a gap analysis as part of their ISBT 128 implementation efforts.

ICCBBA creates the Enterprise Grant aimed at supporting organizations working in resource limited countries that develop initiatives that have an impact on information management or traceability.

ICCBBA releases version 1.0 of an implementation guide on blood transfusion for resource limited countries is published. The intended audiences of this document are blood transfusion services and hospital blood banks.

Enterobiotics, Ltd. In Scotland becomes the first fecal microbiota facility that registers with ICCBBA.

ICCBBA releases version 1.0 of the Single European Code Builder Tool.

AABB, FACT, JACIE, and NMDP require that ISBT 128 terminology be used when labeling cellular therapy products. AABB Standards for Cellular Therapy requires that all facilities shall implement ISBT 128 labeling by 01 July 2018.

The Eye Bank Association of America (EBAA) requires ISBT 128 barcoding for international shipments for eye banks in North America. ICCBBA releases a guidance document (IG-040) in relation to this.

The first Enterprise Grant is awarded to Global Healing, a nonprofit organization based in Berkeley, California, for its proposal to strengthen the quality management system of the blood bank at the Hôpital Universitaire de Mirebalais (HUM) in Haiti.

ICCBBA releases version 1.0 of the Cellular Therapy Audit Tool. The tool is intended for auditors to help them assess compliance to ISBT 128 requirements for cellular therapy products as well as used by facilities wanting to perform a self-assessment or a gap analysis as part of their ISBT 128 implementation efforts.
As of September 2019, there exists 15,707 Product Description Codes across all product categories including blood, cellular therapy, ocular tissues, reproductive tissues, regenerative tissues, organs, milk, fecal microbiota, topical, and other products.

As of July 31st 2019, ICCBBA has 5,401 active facilities registered and growing. There are 4,590 Blood, 911 Cell Therapy, 143 Tissue, 119 Ocular, 55 Reproductive, 10 Milk, 5 Medical Device, and 2 Fecal facilities.

ICCBBA host Forum 25 in Lisbon, Portugal to celebrate 25th Anniversary.